LUJAN Hugo Daniel
congresos y reuniones científicas
Development of an oral vaccine against Tuberculosis base on Virus-like particles
MARTINA MARIANA A; RUPIL LUCÍA LARA; SERRADELL MARIANELA C; GARCIA VE; MARIA ISABEL COLOMBO; BEROD L; SPARWASSER T; LUJAN HUGO DANIEL
Congreso; 52 th Annual Meeting Argentine Society for Biochemistry and Molecular Biology; LII Reunión Anual Sociedad Argentina de Investigación en Bioquímica y Biología Molecular; 2016
An effective vaccine isurgently needed to fight tuberculosis (TB), the leading cause of death from asingle infectious agent worldwide. BCG is the only currently available TBvaccine but it is virtually not effective against adult pulmonary TB. Clinicaltrials suggest that other systemic vaccines have little advantageover BCG and that mucosal vaccines seem to provide better protection. The goalof our work is to produce an oral vaccine for TB by means of the generation ofvirus-like particles (VLPs) pseudotyped with Variant-specific SurfaceProteins (VSPs) from Giardia lamblia and containing Mycobacterium tuberculosis (Mtb) specific antigens. VLPs arehighly immunogenic and also safe and non-infectious. VSPs not only areresistant to proteases and low pH but also show adjuvant activity. We were able to expressin HEK cells, expressing or not in their surface the extracellular domain of Giardia VSP1267, the Mo-MLV capsidprotein GAG fused to ESAT-6, CFP-10 and Ag85B Mtb antigens. These proteinsself-assembled into VLPs with or without VSPs on their surface, and wereefficiently purified from the cell supernatant. Initial analysis of oralimmunization of mice showed that the VLPs are capable of generating humoral andcellular immune responses against Mtb recombinant antigens. Further studies willprovide new insights regarding the efficacy of this formulation to avoid Mtbinfections.